CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
G-Pen Mini™ (glucagon injection) +2 moredrug
Likely dose
G-Pen Mini™ (glucagon injection) 150 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02660242
NCT02660242Phase 2Completed
CompareCT.gov

The Use of Mini-dose Glucagon to Prevent Exercise-induced Hypoglycemia in Type 1 Diabetes

Jaeb Center for Health Research·interventional·Posted Jan 21, 2016·Updated Mar 3, 2020

In Brief

A Phase 2 clinical trial evaluating G-Pen Mini™ (glucagon injection), Glucose Tabs, and 1 other intervention for Diabetes Mellitus, Type 1. Completed, enrolled 16 participants across 2 sites.

Detailed Summary

This project focuses on development of new strategy for the prevention of exercise-associated hypoglycemia using mini-dose glucagon.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 1
CountriesUnited States
CollaboratorsXeris Pharmaceuticals

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 21, 2016
Enrollment StartJan 1, 2016
Primary CompletionFeb 15, 2017
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 10.4 years ago

Interventions

G-Pen Mini™ (glucagon injection)drug

Glucagon (150 µg) 5 minutes before the start of exercise (SQ-abdomen).

Glucose Tabsother

Dextrose tabs orally (20 grams) 5 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).

Basal Insulin Reductionother

Basal insulin reduction to 50% 5 minutes before the start of exercise.